Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down – Here’s What Happened

Genmab A/S (OTCMKTS:GNMSF) shares gapped down prior to trading on Tuesday . The stock had previously closed at $274.75, but opened at $252.70. Genmab A/S shares last traded at $252.70, with a volume of 47 shares changing hands.

Genmab A/S Stock Performance

The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The company has a market capitalization of $16.32 billion, a PE ratio of 17.12 and a beta of 0.94. The company has a 50 day moving average price of $295.82 and a 200 day moving average price of $306.18.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.